Mertansine (DM1) featured
DM1 offers 5 main sections: 1 - THE STEP SEQUENCER frees your imagination with a smart use of the multi-touch screen. 3 months free with 1-year plan. Download Information. Please select type of product and model. FOR LAPTOPS: The serial number can be found on the bottom of the laptop or on the box. The serial number should start with 'NKN' or 'NKP' signs.
Download DM1 for free. The goal of the DM1 project is build a Relational Database System that is suitable for educational purposes. DM1 will not be a production strength database. How to install Dm1 Pro s Software? Pl/en/drivers and download Pro S. Original Poster 2 points 2 years ago. Thanks just what i need.
We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA
WARNING: This product is for research use only, not for human or veterinary use.
CAS#: 139504-50-0
Description: Mertansine refers to the thiol-containing maytansinoid, DM1 (N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with an SPP (N-succinimidyl 4-(2-pyridyldithio)) linker to create an antibody-drug conjugate or ADC. Experimental ADCs with the SPP-DM1 design include lorvotuzumab mertansine. DM1 can also be linked to an antibody using the SMCC (4-(3-mercapto-2,5-dioxo-1-pyrrolidinylmethyl)-cylohexanecarboxylic acid) linker, in which case the International Nonproprietary Name of the conjugate formed contains the word emtansine. DM1 and its attachment via these linkers result from ImmunoGen Inc research. Trastuzumab emtansine (T-DM1) is an anti-HER2/neu antibody-drug conjugate.
Price and Availability
Pricing updated 2020-10-18. Prices are subject to change without notice.
Mertansine, purity > 98%, is in stock. The same day shipping out after order is received. Chemical Structure
Theoretical Analysis
MedKoo Cat#: 123212
Name: Mertansine (DM1)
CAS#: 139504-50-0
Chemical Formula: C35H48ClN3O10S
Exact Mass: 737.27489
Molecular Weight: 738.29
Elemental Analysis: C, 56.94; H, 6.55; Cl, 4.80; N, 5.69; O, 21.67; S, 4.34
Name: Mertansine (DM1)
CAS#: 139504-50-0
Chemical Formula: C35H48ClN3O10S
Exact Mass: 737.27489
Molecular Weight: 738.29
Elemental Analysis: C, 56.94; H, 6.55; Cl, 4.80; N, 5.69; O, 21.67; S, 4.34
Synonym: DM1; DM-1; DM 1; DM1 Compound; DM1 [Maytansinoid]; Maytansinoid DM 1; Maytansinoid DM1; Maytansinoid DM-1; UNII-DDZ29HGH0E; maytansine, Mertansine; emtansine;
IUPAC/Chemical Name: (14S,16S,33S,2R,4R,10E,12Z,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(3-mercaptopropanoyl)-N-methyl-L-alaninate
InChi Key: ANZJBCHSOXCCRQ-GCRZMMRQSA-N
InChi Code: InChI=1S/C35H48ClN3O10S/c1-19-10-9-11-26(46-8)35(44)18-25(47-33(43)37-35)20(2)31-34(4,49-31)27(48-32(42)21(3)38(5)28(40)12-13-50)17-29(41)39(6)23-15-22(14-19)16-24(45-7)30(23)36/h9-11,15-16,20-21,25-27,31,44,50H,12-14,17-18H2,1-8H3,(H,37,43)/b11-9-,19-10+/t20-,21+,25+,26-,27-,31?,34+,35+/m1/s1
SMILES Code: C[C@@H]1[C@@H]2C[C@]([C@@H](/C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@H]([C@]4(C1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCS)C)/C)OC)(NC(=O)O2)O
Technical Data
White to off-white solid powder
>98% (or refer to the Certificate of Analysis)
View CoA: current batch, Lot#A7T12K27
View CoA: current batch, Lot#C20R04B15
View CoA: current batch, Lot#C20R04B15
View QC data: current batch, Lot#A7T12K27
View QC data: current batch, Lot#C20R04B15
View QC data: current batch, Lot#C20R04B15
View Safety Data Sheet (SDS)
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Dm1 2 1 Download Free Version
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Soluble in DMSO, not in water
>2 years if stored properly
This drug may be formulated in DMSO
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
2934.99.9001
Additional Information
Mertansine is a tubulin inhibitor, meaning that it inhibits the assembly of microtubules by binding to tubulin (at the rhizoxin binding site). The monoclonal antibody binds specifically to a structure (usually a protein) occurring in a tumour, thus directing mertansine into this tumour. This concept is called targeted therapy.
The following (experimental) drugs are antibody-drug conjugates (ADC) combining monoclonal antibodies with mertansine as the cytotoxic component. Mertansine is linked via 4-mercaptovaleric acid.
The following (experimental) drugs are antibody-drug conjugates (ADC) combining monoclonal antibodies with mertansine as the cytotoxic component. Mertansine is linked via 4-mercaptovaleric acid.
References
1: Koniev O, Kolodych S, Baatarkhuu Z, Stojko J, Eberova J, Bonnefoy JY, Cianférani S, Van Dorsselaer A, Wagner A. MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation. Bioconjug Chem. 2015 Sep 3. [Epub ahead of print] PubMed PMID: 26335849.
2: Van den Mooter T, Teuwen LA, Rutten A, Dirix L. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Expert Opin Biol Ther. 2015 May;15(5):749-60. doi: 10.1517/14712598.2015.1036026. PubMed PMID: 25865453.
3: Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam MH, Hu W, Charati MB, Khandke K, Kim KS, Cinque M, Lucas J, Graziani E, Maderna A, O'Donnell CJ, Arndt KT, Gerber HP. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015 Apr;14(4):952-63. doi: 10.1158/1535-7163.MCT-14-0862. Epub 2015 Feb 2. PubMed PMID: 25646013.
4: Robak T, Robak E. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2014 Jul;23(7):911-24. doi: 10.1517/13543784.2014.908184. Epub 2014 Apr 7. Review. PubMed PMID: 24708159.
5: Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8. PubMed PMID: 24492307; PubMed Central PMCID: PMC3984343.
6: Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark Ed). 2014 Jan 1;19:163-70. Review. PubMed PMID: 24389179.
7: Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Aug 1;16(4):419. doi: 10.1186/s13058-014-0419-5. Erratum in: Breast Cancer Res. 2014;16(6):468. PubMed PMID: 25928889; PubMed Central PMCID: PMC4429364.
8: Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. Buy luts. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24. PubMed PMID: 23798344; PubMed Central PMCID: PMC4260400.
9: van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013 Aug;14(12):1569-73. doi: 10.1517/14656566.2013.805746. Epub 2013 May 31. PubMed PMID: 23721099.
10: Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013 May;73(7):755-65. doi: 10.1007/s40265-013-0050-2. Review. PubMed PMID: 23620199.
11: Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P, Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y, Fridman E, Meir K, Simon A, Magister M, Kaminski N, Goldmacher VS, Harari-Steinberg O, Dekel B. The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. EMBO Mol Med. 2013 Jan;5(1):18-37. doi: 10.1002/emmm.201201516. Epub 2012 Dec 13. PubMed PMID: 23239665; PubMed Central PMCID: PMC3569651.
12: Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review. PubMed PMID: 23173552; PubMed Central PMCID: PMC3731599.
13: Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs. 2012 Nov-Dec;4(6):637-47. doi: 10.4161/mabs.21697. Epub 2012 Aug 22. PubMed PMID: 22909934; PubMed Central PMCID: PMC3502230.
14: Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012 Dec;14(4):799-805. doi: 10.1208/s12248-012-9386-x. Epub 2012 Aug 9. Review. PubMed PMID: 22875610; PubMed Central PMCID: PMC3475867.
15: Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, Krause M, Baumann M. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol. 2012 Mar;102(3):444-9. doi: 10.1016/j.radonc.2011.10.013. Epub 2011 Nov 17. PubMed PMID: 22100655.
16: Ricart AD. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther. 2011 Apr;89(4):513-23. doi: 10.1038/clpt.2011.8. Epub 2011 Mar 2. Review. PubMed PMID: 21368753.
17: Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008 Jul-Aug;5(4):474-86. doi: 10.1021/mp800024g. Weathersnoop 4 1 99. Epub 2008 Jun 3. Review. PubMed PMID: 18547053; PubMed Central PMCID: PMC2772999.
18: Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27. PubMed PMID: 18301896.
19: Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008 Sep;44(9):823-9. doi: 10.1016/j.oraloncology.2007.10.009. Epub 2008 Jan 18. PubMed PMID: 18203652.
20: Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn HP, Sohn C, Schneeweiss A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs. 2007 Apr;18(4):477-85. PubMed PMID: 17351401.
Driver
The DM1 PRO S runs straight out of the box with no need for additional software. Its DPI settings are saved to its onboard memory and can currently not be changed. Having no software does mean you can only set its DPI to a preset. It also means there is no way to change the LED color to your favorite without actually changing the DPI.Dream Machines made this sacrifice to ensure there are no problems or conflicts whilst using the mouse, and because it keeps pricing low.
Performance
Again, the performance of the DM1 PRO S is outstanding. I played the usual games I test mice with, including Overwatch, CS:GO, Total War, etc., and have also used it for photo editing and general use, and I have been very impressed. It is comfortable to use and its upgraded sensor gives us an even higher DPI; now up to 12,000 and with increased tracking speeds of up to 7 M/S. The 3360 can also track on far more surfaces, but I never had a problem with the 3310 whilst tracking.Dream Machines boasts that they have turned off many of the features we usually see, such as prediction, smoothing, and acceleration. Quite honestly, I couldn't tell that much of a difference until the DPI was so high I wasn't able to use it accurately anyway. The lift-off distance (LOD) is perfect for me, though. Set at 1.8 mm, it really is spot on, unlike some other mice with a higher LOD I am currently testing, which makes them track when I don't want them to as I reposition them; there is no such problem with the DM1 Pro.
Dm1 2 1 Download Free Pc Games
The switches for this mouse are also excellent; the Omron main switches have a satisfying click whilst not being too stiff or loud, the middle button has apparently changed, as mentioned, but I couldn't tell a noticeable difference. The side buttons feel great once again.
One thing I still don't like is the breathing effect that comes with the DM1 PRO and the DM1 PRO S. To me, it just doesn't add anything. I would prefer a solid color. You can't stop or change this effect.
This is not an effect since I am simply pressing the DPI button to change the DPI of the mouse, which is represented by a different color depending on which DPI I set it to; 400 / 800 / 1600 / 2400 / 4800 / 12000. You can't change the DPI outside of these parameters due to the lack of software.
The lighting for the DM1 PRO S is bright enough to be seen in daylight, so people will know the brand of mouse regardless of the color.
Dm1 2 1 download free. full
Dm1 2 1 Download Free Download
As well as having LEDs illuminate the logo, there are those that illuminate the scroll wheel by giving off this rather nice effect.